Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Fate Therapeutics (FATE) over the last 12 years, with Q3 2025 value amounting to $3.9 million.

  • Fate Therapeutics' Other Accumulated Expenses fell 6325.97% to $3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.9 million, marking a year-over-year decrease of 6325.97%. This contributed to the annual value of $6.4 million for FY2024, which is 2166.79% down from last year.
  • As of Q3 2025, Fate Therapeutics' Other Accumulated Expenses stood at $3.9 million, which was down 6325.97% from $4.9 million recorded in Q2 2025.
  • Fate Therapeutics' 5-year Other Accumulated Expenses high stood at $19.2 million for Q4 2022, and its period low was $3.9 million during Q3 2025.
  • Moreover, its 5-year median value for Other Accumulated Expenses was $8.6 million (2023), whereas its average is $10.2 million.
  • As far as peak fluctuations go, Fate Therapeutics' Other Accumulated Expenses surged by 18318.91% in 2021, and later crashed by 6372.36% in 2025.
  • Over the past 5 years, Fate Therapeutics' Other Accumulated Expenses (Quarter) stood at $11.7 million in 2021, then soared by 63.75% to $19.2 million in 2022, then tumbled by 57.66% to $8.1 million in 2023, then decreased by 21.67% to $6.4 million in 2024, then plummeted by 39.35% to $3.9 million in 2025.
  • Its last three reported values are $3.9 million in Q3 2025, $4.9 million for Q2 2025, and $6.8 million during Q1 2025.